Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · September 24, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04224272). This is a study registration, not published results. Lead sponsor: Jazz Pharmaceuticals. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 51 participants (ACTUAL). Conditions: HER2+/HR+ Breast Cancer. Interventions: DRUG: ZW25 (Zanidatamab); DRUG: Palbociclib; DRUG: Fulvestrant. Primary outcome measures: Number of Participants With Dose-Limiting Toxicities , Cycle 1 Day 1 to Day 28 (each cycle is 28 days); Number of Participants Reporting Grade 3 or Higher Treatment-emergent Adverse Events , From the start of dosing of any study drug up until 30 days after last study dose, up to approximately 5 years 20 days.; Progression-free Survival 6 , 6 months from first dose of all study drugs to the date of documented disease progression or death. Brief summary: This is a multicenter, Phase 2a, open-label, 2-part study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) in combination with palbociclib plus fulvestrant. Eligible patients include those with locally advanced (unresectable) and/or metastatic human epidermal growth factor receptor 2 (HER2)-positive, hormone receptor (HR)-positive breast cancer.